NPI 1922005370: Open Payments
NPI 1922005370. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,580 in 77 payments from 13 companies in 2025. Trend: 2023 $2,229 · 2024 $2,444 · 2025 $1,580
Food & beverage: $1,580
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 32 | $638 |
| Amgen Inc. | 11 | $317 |
| ABBVIE INC. | 12 | $167 |
| AstraZeneca Pharmaceuticals LP | 9 | $139 |
| Radius Health, Inc. | 2 | $117 |
| GlaxoSmithKline, LLC. | 2 | $37 |
| Lilly USA, LLC | 2 | $35 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $33 |
| Exact Sciences Corporation | 1 | $26 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $20 |
Products named: Ozempic, EVENITY, Wegovy, VRAYLAR, Repatha, Tymlos, Rybelsus, BREZTRI.
